National Bank of Canada FI Purchases 126,528 Shares of Hologic, Inc. (NASDAQ:HOLX)

National Bank of Canada FI increased its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 196.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 190,912 shares of the medical equipment provider's stock after purchasing an additional 126,528 shares during the quarter. National Bank of Canada FI owned approximately 0.08% of Hologic worth $15,551,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. EP Wealth Advisors LLC bought a new stake in shares of Hologic in the 3rd quarter valued at $811,000. Insigneo Advisory Services LLC bought a new position in shares of Hologic during the 3rd quarter valued at about $457,000. Worldquant Millennium Advisors LLC grew its position in shares of Hologic by 200.0% in the 3rd quarter. Worldquant Millennium Advisors LLC now owns 184,170 shares of the medical equipment provider's stock valued at $15,002,000 after purchasing an additional 122,784 shares during the period. Wahed Invest LLC increased its stake in Hologic by 8.3% during the 3rd quarter. Wahed Invest LLC now owns 5,551 shares of the medical equipment provider's stock worth $452,000 after purchasing an additional 424 shares in the last quarter. Finally, Weiss Asset Management LP acquired a new stake in Hologic during the 3rd quarter worth approximately $15,291,000. 94.73% of the stock is owned by institutional investors.

Hologic Stock Performance

Shares of HOLX traded down $1.30 during mid-day trading on Wednesday, reaching $75.53. The company's stock had a trading volume of 3,159,135 shares, compared to its average volume of 1,617,876. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 1-year low of $68.15 and a 1-year high of $84.67. The business has a 50-day simple moving average of $79.62 and a two-hundred day simple moving average of $78.60. The stock has a market cap of $17.14 billion, a P/E ratio of 23.07, a PEG ratio of 2.37 and a beta of 0.96.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.01. The company had revenue of $987.90 million during the quarter, compared to analysts' expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic's quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.89 EPS. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company's stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.75% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

HOLX has been the subject of several research analyst reports. Royal Bank of Canada upped their price target on shares of Hologic from $86.00 to $89.00 and gave the company a "sector perform" rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price target on Hologic from $92.00 to $94.00 and gave the company an "overweight" rating in a research note on Tuesday, November 5th. Mizuho decreased their price objective on Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Tuesday, November 5th. UBS Group upped their price target on Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Finally, Raymond James lifted their price objective on shares of Hologic from $93.00 to $95.00 and gave the company an "outperform" rating in a report on Tuesday, November 5th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $89.50.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.